Status:
COMPLETED
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Nonalcoholic Fatty Liver Disease (NAFLD)
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is mainly considered a nutrition-related disease and life-style/diet interventions showed some promising results. But in spite of this, there are no available ...
Detailed Description
Factors driving progression from steatosis (NAFL) to steatohepatitis (NASH) in patients with non-alcoholic fatty liver disease (NAFLD) remain largely unknown. Considerable data now indicate that steat...
Eligibility Criteria
Inclusion
- \- histological proven NAFLD (liver biopsy \<6 months); hospitalised or outpatients followed up for NAFLD; patients giving their consent for the study; patients covered by health insurance.
Exclusion
- history of excessive alcohol consumption (\>20 g/day for males and \>10 g/day for females) or other cause of liver injury (viral hepatitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, drug-induced hepatitis, or others); cirrhosis; ongoing hypolipemiant treatment; diabetes; Chronic diarrhea; severe associated disease;Taking antibiotics or probiotics in the last 3 months; Chronic inflammatory bowel disease; Weight ≤70Kg and hemoglobin level ≤7g/dl; Allergy to or refusal of any of the elements of the meal provided.
Key Trial Info
Start Date :
February 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03836443
Start Date
February 14 2019
End Date
June 22 2023
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kremlin Bicetre hospital
Le Kremlin-Bicêtre, France